Comparison of the effectiveness of amlodipine and telmisartan in macrovascular and microvascular complications in type2 diabetes mellitus patients with hypertension

  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
  • strict warning: Declaration of content_handler_field::options() should be compatible with views_object::options() in /home4/vibu/public_html/journalcra.com/sites/all/modules/cck/includes/views/handlers/content_handler_field.inc on line 208.
  • strict warning: Declaration of views_handler_filter::options_validate() should be compatible with views_handler::options_validate($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_handler_filter::options_submit() should be compatible with views_handler::options_submit($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_plugin_style_default::options() should be compatible with views_object::options() in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_style_default.inc on line 25.
  • strict warning: Declaration of views_plugin_row::options_validate() should be compatible with views_plugin::options_validate(&$form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Declaration of views_plugin_row::options_submit() should be compatible with views_plugin::options_submit(&$form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
  • strict warning: Declaration of views_handler_filter_boolean_operator::value_validate() should be compatible with views_handler_filter::value_validate($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter_boolean_operator.inc on line 149.
  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
Author: 
Ameera, P. M., Shamna Sadan and Dr. Anoop Kumar
Subject Area: 
Health Sciences
Abstract: 

Back ground and Objectives: Antihypertensive drugs Amlodipine and Telmisartan are used to control blood pressure and reduce macro and microvascular complications in diabetic patients with hypertension. Telmisartan is an angiotensin II receptor antagonist used in the management of hypertension. Telmisartan is a partial agonist of peroxisome proliferator –activated receptor. So this lower the risk of acute myocardial infarction, stroke, or heart failure in diabetic patients. Amlodipine is a calcium channel blocker. It works to control blood pressure and reduce the number of angina attacks by widening and relaxing blood vessels. The main objective of the study is to evaluate effectiveness of amlodipine and telmisartan in macrovascular (cardiovascular) and microvascular (nephropathic) complications in type 2 diabetes mellitus patients with hypertension. Methods: A prospective, cross sectional study conducted in type 2 diabetes patients with hypertension at general medicine inpatients and outpatients department in a 500 bed tertiary care teaching hospital. After obtaining the consent Patients were categorised into 2 groups, one group treated with Amlodipine (5mg\day) and other group treated with Telmisartan 40(mg\day). Patients are evaluated for the parameter like blood pressure and echocardiograph to detect cardiovascular complication microalbumin and serum creatinine to detect nephropathic complications at baseline and follow up after 6 week. Results and Discussion: A total of 60 patients were evaluated (30 patients in each group), with a predominance of male (51%) in both groups. After 6 weeks of treatment, the Amlodipine and Telmisartan group no significant difference in SBP (131mmHg and 127mmHgrespectively.P=0.206), and DBP (86.67mmHg and 82.67mmHg respectively, p=0.076), although the values were slightly lower in Telmisartan group. In the case of serum creatinine, in amlodipine group it about 1.28 and 1.23 in Telmisartan group. Serum creatinine value lower in Telmisartan group, but there is no significant difference (p value about 0.656). After 6 weeks of treatment with Amlodipine microalbumine present in 20% of patients and it present but decreased in 26.7% and it not present in 53.3%patients.in Telmisartan group it not present in 63.3%patients,present but it decreased in 16.7% and present in 20% patients. Telmisartan group has higher reduction in microalbumine compared to that of Amlodipine group. When comparing ECHO of the two groups after 6 weeks of treatment, in Amlodipine group 70% of the patients have complication present but decreased. Complication not present in 30% of patients.in the case Telmisartan group complication not present in 56.7% patients and complication present but decreased in 43.3% patients. Conclusion: The result of the study shows that after 6 weeks of treatment, there is no significant difference between laboratorical parameters in two groups. The result shows the effectiveness of Amlodipine and telmisartan in macrovascular (cardiovascular complication detected from ECHO) and microvascular complication (nephropathy detected by checking microalbuminuria and serum creatinine) are almost same. Telmisartan shows higher reduction in parameters like SBP, DBP, SC and microalbumine compared to Amlodipine group. Amlodipine show higher reduction in uric acid and fasting blood sugar compared to Telmisartan group.

PDF file: 

Editorial Board Member's

Dr.Geetanjali Joshi Mishra
Lucknow, UP, INDIA
Dr. Sankalp Verma
India
Tannu Arora
India
Prof Dr. Lee Mun Seng
Malaysia
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
Dr. Lim Gee Nee
Malaysia
DANA MOHAMMED
UK
Ali Majnoony Tootakhaneh
Iran
Prof. Somchai Amornyotin
Thailand
Nurhodja Akbulaev
Turkey
Muhammad Hamid
Pakistan
MOHAMMAD GHOLAMI
Iran
MAVLYANOV ISKANDAR RAKHIMOVICH
Uzbekistan
Hasan Ali Abed Al-Zu’bi
Jordan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Eapen, Asha Sarah
USA
Dr. Ruchika Khanna
India
DR. MUHAMMAD ISMAIL MOHMAND
UK
DR. MAHESH SHIVAJI CHAVAN
India
Dr. Lokesh Gambhir
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Charu Bisaria
India
Dr. Achmad Choerudin
Indonesia
Bensafi Abd-El-Hamid
Algeria
Dr. Pralhad Kanhaiyalal Rahangdale
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Arun Kumar
India
DR. M. ARUNA
India
ALIIHSAN SEKERTEKIN
Turkey
Yassine KADMI
French
Tariqual Islam Sajeeb
Dhaka
Jiban Shrestha
Nepal
Fredrick OJIJA
Tanzanian
Dr. Rasha Ali Eldeeb
Egypt
DR. PATRICK D. CERNA
Philippines
Dr. Amzad Basha Kolar
India
Prof. Suhail Hussein Al-Fatlawi
Iraq
ZiedIBN El Hadj
Tunisia
Zafer Omer Ozdemir
Turkey
Uthumporn Utra
Malasiya
Tarek Habeeb Ramadan Ahmed
Egypt
Syed Abdul Rehman Khan
China
Sri. P.C. Puri
India
Dr. Mohd Ramzi Bin Mohd Hussain
Malasiya
Peter Changilwa Kigwilu
Africa
P. Rajasulochana
India
Nam Nguyen Dang
Vietnam
Lachachi Abdelheq
Algerie
Ibrahim Khider Ibrahim Osman
Sudan
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Elsadig Gasoom FadelAlla Elbashir
Sudan
Dr. Zafar Iqbal
Pakistan
DR. Yogesh Dnyandeo Narkhede
India
Dr. Recep TAS
Turkey
Dr. Mustafa Y.G. Younis
Libiya
Dr. Ashok Kumar
India
Arshad Mehmood
Pakistan
Anania B. Aquino
Phillippines
Ahmed I.S. Ahmed
Egypt
Yaling Lin
Taiwan
Souhir Neifar
Tunisia
Nihad Abdel Latif Ali Kadhim
Iraq
Muhammad Aslam
Pakistan
Dr. Shahera S.Patel
India
Dr. Nicolas Padilla-Raygoza
Mexico
Dr. Jatinder Pal Singh Chawla
India
Dr. Devendra Kumar Gupta
India
Diones Krinski
Brasil
Aberham Kebedom Darge
Ethiopia
Atiya Firdous
Pakistan
Prof. Marco Nemesio E.Montano
Phillippines
Prof. Zora Singh
AUSTRALIA
Dr. Alaa Fahmy Mohamed
Egypt
Moataz Mostafa El-Nahas Ali El-sherbini
Egypt
Prof. M. Abdul Mottaleb
Maryville
Dr. Ali Seidi
Iran